Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Sees Large Increase in Short Interest

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 10,334,707 shares, a growth of 33.0% from the December 15th total of 7,772,345 shares. Currently, 5.3% of the company’s stock are sold short. Based on an average daily volume of 1,680,832 shares, the days-to-cover ratio is currently 6.1 days. Based on an average daily volume of 1,680,832 shares, the days-to-cover ratio is currently 6.1 days. Currently, 5.3% of the company’s stock are sold short.

Zimmer Biomet Stock Performance

NYSE ZBH traded down $1.33 during trading on Monday, hitting $87.42. The company’s stock had a trading volume of 2,681,302 shares, compared to its average volume of 1,825,838. Zimmer Biomet has a 52 week low of $85.33 and a 52 week high of $114.44. The firm has a market cap of $17.32 billion, a P/E ratio of 21.64, a price-to-earnings-growth ratio of 2.23 and a beta of 0.62. The firm has a 50 day moving average price of $91.59 and a 200 day moving average price of $96.50. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. Zimmer Biomet’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Robert W. Baird reiterated a “neutral” rating and set a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a research note on Wednesday, November 5th. Baird R W lowered Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 16th. Finally, BTIG Research reiterated a “buy” rating and set a $112.00 price target on shares of Zimmer Biomet in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $107.33.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently modified their holdings of ZBH. Dodge & Cox increased its position in shares of Zimmer Biomet by 12.9% during the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the period. Norges Bank acquired a new stake in Zimmer Biomet during the second quarter worth $225,867,000. AQR Capital Management LLC increased its holdings in Zimmer Biomet by 276.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after buying an additional 955,284 shares during the period. Capital International Investors raised its stake in shares of Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after buying an additional 778,467 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 15.2% during the 2nd quarter. Franklin Resources Inc. now owns 4,673,860 shares of the medical equipment provider’s stock worth $426,303,000 after acquiring an additional 615,014 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.